CNR1 and fatty liver disease: A previous study indicated that CB1 blockade, rimonabant, reduced obesity‐mediated hepatic steatosis due to suppression of hepatic proinflammatory cytokine levels in both diet‐induced obese mice and obese Zucker fa/fa rats.17